Analysis CC
Chemours' profit jump comes with a smaller annual cash forecast
A $150 million payment for insurance rights lifts the quarterly result. Comparing the old and new outlook shows a sharp cut in expected operating cash.
Chemours now expects $120 million to $160 million of free cash flow for 2026, down from the $195 million to $245 million it forecast in August. That is cash from operations after capital spending.
The reduction comes alongside a much larger reported quarterly profit: $196 million, versus a revised $46 million a year earlier. A payment connected with legacy chemical litigation helps explain the gap between the two headlines.
The cash forecast shrinks faster than investment spending
Research by Ticker Byline shows that the new forecast cuts expected annual operating cash by $120 million at the midpoint. Chemours also cut planned capital spending by $40 million. That cushions the fall, leaving an $80 million reduction in expected free cash flow, or 36%.
The table compares annual forecasts in USD millions.
| Annual forecast | August | November |
|---|---|---|
| Operating cash flow | 445–525 | 340–390 |
| Capital spending | 250–280 | 220–230 |
| Free cash flow | 195–245 | 120–160 |
What lifted the reported profit
Chemours received $150 million under an agreement covering insurance rights related to PFAS, a group of chemicals involved in its legacy pollution cases. It exchanged rights to certain future insurance proceeds for money paid into a settlement escrow.
The payment reduced overhead expenses in Q3. Gains on asset sales also increased to $50 million from $7 million. After the company's adjustments for legal, environmental, asset-sale and other items, net income was $31 million, compared with $26 million a year earlier.
The payment also appears in operating cash flow. Chemours received the $150 million in restricted cash and used approximately $100 million for New Jersey settlement payments. It also paid about $25 million of taxes associated with its Taiwan property sale.
Reported Q3 free cash flow was $98 million, below last year's $105 million.
Pricing gains meet weaker refrigerant sales
Chemours' pigment business, Titanium Technologies, raised prices 10% and increased adjusted EBITDA to $85 million from $25 million. That earnings measure removes interest, taxes, depreciation, amortization and selected other items.
Those gains helped offset weaker refrigerants: Opteon sales fell 22% to $287 million as the North American air-conditioning aftermarket worked through earlier inventory buildup.
Chemours narrowed its annual adjusted EBITDA forecast to $775 million to $800 million, lowering the upper end from $825 million. The Q3 result of $200 million was within August's $175 million to $205 million range.
The Chemours company profile follows the cash forecast, business results, settlement funding and completed Taiwan property sale.